Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.74 |
| ▸ | KDR | P35968 | 13/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | GOT1 | P17174 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MPO | P05164 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.62 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479267 | 0.88 | EGFR (0.76) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL31426459 | 0.88 | EGFR (0.76) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL10356806 | 0.85 | EGFR (0.72) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL6606282 | 0.85 | KDR (0.72) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL13286756 | 0.84 | NPC1 (0.71) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL3768687 | 0.80 | EGFR (0.71) | EGFRKDRKDM4ETP53CYP3A4 | |
| Hydralazine SCHEMBL3995896 | 0.77 | ALDH1A1 (1.00) | EGFRKDRKDM4ETP53CYP3A4 | |
| Hydralazine SCHEMBL7810 | 0.77 | ALDH1A1 (1.00) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL28900093 | 0.76 | NPC1 (0.71) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL13056966 | 0.76 | EGFR (0.59) | EGFRKDRTP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | EGFR 3245/4885KDR 2808/4885KDM4E 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.